NECFA
CYTK icon

New England Capital Financial Advisors’s Cytokinetics CYTK Stock Holding History

New England Capital Financial Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$48 – 402
2024
Q4 		$48 Hold
1
– – ﹤0.01% 406
2024
Q3 		$53 Hold
1
– – ﹤0.01% 393
2024
Q2 		$55 Hold
1
– – ﹤0.01% 398
2024
Q1 		$71 Hold
1
– – ﹤0.01% 391
2023
Q4 		$84 Hold
1
– – ﹤0.01% 392
2023
Q3 		$30 Hold
1
– – ﹤0.01% 392
2023
Q2 		$33 Hold
1
– – ﹤0.01% 388
2023
Q1 		$36 Hold
1
– – ﹤0.01% 431
2022
Q4 		$42 Buy
+1
New +$43 ﹤0.01% 435

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

New England Capital Financial Advisors's CYTK Position: Q1 2025 in Review

New England Capital Financial Advisors sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 1 share — an estimated $48 sold.

New England Capital Financial Advisors first reported a position in CYTK in Q4 2022 and held it in 9 quarters. The position peaked at $84 in Q4 2023. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • New England Capital Financial Advisors reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • New England Capital Financial Advisors sold 1 Cytokinetics share in Q1 2025, an estimated $48.
  • New England Capital Financial Advisors first reported a position in Cytokinetics in Q4 2022 and held it in 9 quarters.
  • New England Capital Financial Advisors's Cytokinetics position peaked at $84 in Q4 2023.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on New England Capital Financial Advisors's 13F filing for Q1 2025, filed 5 May 2025.